Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Andrew M, Skinner"'
Autor:
Jonathan D. Baghdadi, Mia Wessel, Erik R. Dubberke, Alison Lydecker, Kimberly C. Claeys, Carolyn Alonso, K.C. Coffey, Michael Durkin, Anne J. Gonzales-Luna, Alice Y. Guh, Jennie H. Kwon, Elise Martin, Preeti Mehrotra, Christopher R. Polage, Michael S. Pulia, Clare Rock, Andrew M. Skinner, Valerie M. Vaughn, Tara Vijayan, Michael E. Yarrington, Daniel J. Morgan, for the CDC Prevention Epicenters Program
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 4 (2024)
Abstract Background: Clostridioides difficile infection (CDI) may be misdiagnosed if testing is performed in the absence of signs or symptoms of disease. This study sought to support appropriate testing by estimating the impact of signs, symptoms, a
Externí odkaz:
https://doaj.org/article/546f64248cc848398d91942e1934cbff
Autor:
Lorinda M. Wright, Andrew M. Skinner, Adam Cheknis, Conor McBurney, Ling Ge, Susan M. Pacheco, David Leehey, Dale N. Gerding, Stuart Johnson
Publikováno v:
Antibiotics, Vol 12, Iss 7, p 1159 (2023)
The COVID-19 pandemic was associated with increases in some healthcare-associated infections. We investigated the impact of the pandemic on the rates and molecular epidemiology of Clostridioides difficile infection (CDI) within one VA hospital. We an
Externí odkaz:
https://doaj.org/article/a0f0d44389b24b08bb18993725e799e9
Autor:
Andrew M. Skinner, Laurica Petrella, Farida Siddiqui, Susan P. Sambol, Christopher A. Gulvik, Dale N. Gerding, Curtis J. Donskey, Stuart Johnson
Publikováno v:
Emerging Infectious Diseases, Vol 26, Iss 2, Pp 247-254 (2020)
During a surveillance study of patients in a long-term care facility and the affiliated acute care hospital in the United States, we identified a Clostridioides difficile strain related to the epidemic PCR ribotype (RT) 027 strain associated with hos
Externí odkaz:
https://doaj.org/article/945053626e5949daad101134aa64833f
Autor:
Johnson, Lorinda M. Wright, Andrew M. Skinner, Adam Cheknis, Conor McBurney, Ling Ge, Susan M. Pacheco, David Leehey, Dale N. Gerding, Stuart
Publikováno v:
Antibiotics; Volume 12; Issue 7; Pages: 1159
The COVID-19 pandemic was associated with increases in some healthcare-associated infections. We investigated the impact of the pandemic on the rates and molecular epidemiology of Clostridioides difficile infection (CDI) within one VA hospital. We an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::6cc63a17a2134594027d4c6a9ba3fdcf
Publikováno v:
New England Journal of Medicine. 388:654-656
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2ef5ebbb740f62dbcbe9da41b976015
https://doi.org/10.1056/nejmclde2204692
https://doi.org/10.1056/nejmclde2204692
Autor:
Susan P. Sambol, Andrew M. Skinner, Fidel Serna-Perez, Benjamin Owen, Dale N. Gerding, Stuart Johnson
Publikováno v:
Microbiology Spectrum. 11
NTCD-M3 is a novel live biotherapeutic, that has been shown in a Phase 2 clinical trial to prevent recurrence of C. difficile infection (CDI) when administered shortly after antibiotic treatment of the initial CDI episode. Fidaxomicin was not, howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5502cc9c71528daeb1a9d642350218f6
https://doi.org/10.1128/spectrum.00517-23
https://doi.org/10.1128/spectrum.00517-23
Autor:
Anne J Gonzales-Luna, Andrew M Skinner, Carolyn D Alonso, Emilio Bouza, Oliver A Cornely, Tim G J de Meij, Richard J Drew, Kevin W Garey, Dale N Gerding, Stuart Johnson, Stacy A Kahn, Haru Kato, Ciaran P Kelly, Colleen R Kelly, Larry K Kociolek, Ed J Kuijper, Thomas Louie, Thomas V Riley, Thomas J Sandora, Maria J G T Vehreschild, Mark H Wilcox, Erik R Dubberke
Publikováno v:
The EXPAND Cdiff group 2023, ' Redefining Clostridioides difficile infection antibiotic response and clinical outcomes ', The Lancet Infectious Diseases . https://doi.org/10.1016/S1473-3099(23)00047-6
With the approval and development of narrow-spectrum antibiotics for the treatment of Clostridioides difficile infection (CDI), the primary endpoint for treatment success of CDI antibiotic treatment trials has shifted from treatment response at end o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caac03cac7016bb23538faa490d630d0
https://doi.org/10.1016/s1473-3099(23)00047-6
https://doi.org/10.1016/s1473-3099(23)00047-6
Publikováno v:
Open Forum Infectious Diseases. 9
Background In 2017, the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiologist of America (SHEA) updated the C. difficile (CD) treatment guidelines recommending vancomycin as the preferred therapy for C. difficile inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c4098134d200a9c239adb5143995cda
https://doi.org/10.1093/ofid/ofac492.484
https://doi.org/10.1093/ofid/ofac492.484
Publikováno v:
Open Forum Infectious Diseases. 9
Background Clostridioides difficile infection (CDI) is an important cause of morbidity and mortality, especially in patients with recurrent episodes and those requiring re-hospitalization. Decreasing recurrent CDI (rCDI) and re-hospitalization for rC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1bb2c5a03eb83ebae905d2d2e5aa52fc
https://doi.org/10.1093/ofid/ofac492.478
https://doi.org/10.1093/ofid/ofac492.478
Publikováno v:
Open Forum Infectious Diseases. 9
Background Omadacycline was approved for the treatment of community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in 2018. Previous studies demonstrate that omadacycline has in vitro activity agai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::113857258eda9c4e5c0887a01bb9c07f
https://doi.org/10.1093/ofid/ofac492.713
https://doi.org/10.1093/ofid/ofac492.713